Vanguard Group
GYRE icon

Vanguard Group’s Gyre Therapeutics GYRE Stock Holding History

Vanguard Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.48M Buy
1,201,589
+51,030
+4% +$394K ﹤0.01% 3044
2025
Q3 		$8.58M Buy
1,150,559
+850
+0.1% +$6.45K ﹤0.01% 3052
2025
Q2 		$8.45M Buy
1,149,709
+53,221
+5% +$464K ﹤0.01% 2995
2025
Q1 		$8.46M Buy
1,096,488
+774,024
+240% +$8.49M ﹤0.01% 2935
2024
Q4 		$3.9M Sell
322,464
-17,707
-5% -$227K ﹤0.01% 3362
2024
Q3 		$4.27M Buy
340,171
+108,530
+47% +$1.4M ﹤0.01% 3327
2024
Q2 		$2.76M Buy
231,641
+36,543
+19% +$501K ﹤0.01% 3463
2024
Q1 		$3.41M Sell
195,098
-2,999
-2% -$54K ﹤0.01% 3431
2023
Q4 		$5.09M Buy
198,097
+184,304
+1,336% +$2.61M ﹤0.01% 3279
2023
Q3 		$99.8K Buy
+13,793
New +$92.4K ﹤0.01% 4348
2023
Q1 		– Sell
-178,099
Closed -$705K – 4560
2022
Q4 		$705K Sell
178,099
-4,969
-3% -$20.3K ﹤0.01% 4015
2022
Q3 		$692K Hold
183,068
– – ﹤0.01% 4115
2022
Q2 		$2.44M Sell
183,068
-2,734
-1% -$18.2K ﹤0.01% 3722
2022
Q1 		$920K Hold
185,802
– – ﹤0.01% 4234
2021
Q4 		$1.27M Sell
185,802
-3,982
-2% -$68.1K ﹤0.01% 4195
2021
Q3 		$5.85M Buy
189,784
+140
+0.1% +$4.61K ﹤0.01% 3553
2021
Q2 		$6.16M Sell
189,644
-14,749
-7% -$506K ﹤0.01% 3480
2021
Q1 		$7.73M Buy
204,393
+73,406
+56% +$3.36M ﹤0.01% 3300
2020
Q4 		$6.2M Buy
130,987
+8,530
+7% +$369K ﹤0.01% 3256
2020
Q3 		$3.95M Sell
122,457
-2,351
-2% -$92K ﹤0.01% 3272
2020
Q2 		$5.49M Buy
124,808
+36,101
+41% +$1.7M ﹤0.01% 3055
2020
Q1 		$2.91M Buy
88,707
+8,267
+10% +$380K ﹤0.01% 3192
2019
Q4 		$4.11M Hold
80,440
– – ﹤0.01% 3229
2019
Q3 		$2.96M Buy
80,440
+1,501
+2% +$80.9K ﹤0.01% 3312
2019
Q2 		$4.36M Buy
78,939
+4,468
+6% +$279K ﹤0.01% 3216
2019
Q1 		$4.53M Buy
74,471
+42,221
+131% +$2.71M ﹤0.01% 3172
2018
Q4 		$1.91M Sell
32,250
-41,308
-56% -$3.05M ﹤0.01% 3393
2018
Q3 		$5.95M Sell
73,558
-327
-0.4% -$25.9K ﹤0.01% 3166
2018
Q2 		$6.47M Buy
73,885
+24,471
+50% +$4.29M ﹤0.01% 3112
2018
Q1 		$9.56M Buy
49,414
+36,994
+298% +$6.9M ﹤0.01% 2843
2017
Q4 		$1.27M Buy
12,420
+4,771
+62% +$243K ﹤0.01% 3551
2017
Q3 		$289K Buy
7,649
+1,820
+31% +$54.6K ﹤0.01% 3848
2017
Q2 		$204K Buy
5,829
+4,350
+294% +$156K ﹤0.01% 3900
2017
Q1 		$104K Buy
1,479
+559
+61% +$32.6K ﹤0.01% 3985
2016
Q4 		$67K Sell
920
-909
-50% -$81.8K ﹤0.01% 4006
2016
Q3 		$249K Sell
1,829
-314
-15% -$47.4K ﹤0.01% 3866
2016
Q2 		$367K Hold
2,143
– – ﹤0.01% 3842
2016
Q1 		$405K Buy
2,143
+1
+0% +$241 ﹤0.01% 3832
2015
Q4 		$754K Buy
2,142
+273
+15% +$107K ﹤0.01% 3710
2015
Q3 		$980K Buy
1,869
+209
+13% +$319K ﹤0.01% 3641
2015
Q2 		$3.65M Sell
1,660
-618
-27% -$1.24M ﹤0.01% 3157
2015
Q1 		$5.33M Buy
2,278
+107
+5% +$221K ﹤0.01% 2969
2014
Q4 		$4.5M Buy
2,171
+809
+59% +$1.56M ﹤0.01% 2954
2014
Q3 		$2.71M Buy
1,362
+126
+10% +$312K ﹤0.01% 3134
2014
Q2 		$4.39M Sell
1,236
-37
-3% -$121K ﹤0.01% 2905
2014
Q1 		$4.76M Buy
1,273
+108
+9% +$400K ﹤0.01% 2855
2013
Q4 		$3.81M Buy
1,165
+92
+9% +$363K ﹤0.01% 2932
2013
Q3 		$4.49M Buy
1,073
+16
+2% +$64.4K ﹤0.01% 2801
2013
Q2 		$3.55M Buy
+1,057
New +$4.02M ﹤0.01% 2850

Other funds holding GYRE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group's GYRE Position: Q4 2025 in Review

Vanguard Group increased its Gyre Therapeutics (GYRE) stake by 4.4% in Q4 2025, buying an estimated $394K and bringing the position to 1,201,589 shares worth $8.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

Vanguard Group first reported a position in GYRE in Q2 2013 and has held it in 49 quarters since. The position peaked at $9.56M in Q1 2018. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.

  • Vanguard Group held 1,201,589 shares of Gyre Therapeutics worth $8.48M as of Q4 2025.
  • Vanguard Group bought 51,030 Gyre Therapeutics shares in Q4 2025, an estimated $394K.
  • Gyre Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3044 holding.
  • Vanguard Group first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Vanguard Group's Gyre Therapeutics position peaked at $9.56M in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.